Dendreon Receives European Patent Covering Provenge® and Company’s ACI Platform Technology


Applied Clinical Trials

SEATTLE, WA, January 15, 2008-Dendreon Corporation today announced that the company has been granted a broad European patent covering the company’s lead product candidate Provenge® (sipuleucel-T), the company’s investigational active cellular immunotherapy for the treatment of advanced prostate cancer. European patent No. 0 870 022 B1 covers the composition of matter of Provenge as well as the company’s other active cellular immunotherapy (ACI) product candidates, such as Neuvenge™ (lapuleucel-T), which utilize Dendreon’s Antigen Delivery Cassette™ technology. The patent also covers methods of activating antigen presenting cells in vitro with certain fusion proteins developed by Dendreon, including the fusion protein that is used in Provenge.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.